287 related articles for article (PubMed ID: 20156115)
1. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT; Pedersen L
Acta Oncol; 2010 Apr; 49(3):305-12. PubMed ID: 20156115
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.
Lash TL; Pedersen L; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Hamilton-Dutoit S; Garne JP; Ewertz M; Sørensen HT
Br J Cancer; 2008 Aug; 99(4):616-21. PubMed ID: 18665165
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
[TBL] [Abstract][Full Text] [Related]
4. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.
Kelly CM; Juurlink DN; Gomes T; Duong-Hua M; Pritchard KI; Austin PC; Paszat LF
BMJ; 2010 Feb; 340():c693. PubMed ID: 20142325
[TBL] [Abstract][Full Text] [Related]
5. Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?
Pritchard KI
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S18. PubMed ID: 21172080
[No Abstract] [Full Text] [Related]
6. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
Cronin-Fenton D; Lash TL; Sørensen HT
Future Oncol; 2010 Jun; 6(6):877-80. PubMed ID: 20528223
[No Abstract] [Full Text] [Related]
7. Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.
Haque R; Shi J; Schottinger JE; Ahmed SA; Cheetham TC; Chung J; Avila C; Kleinman K; Habel LA; Fletcher SW; Kwan ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26631176
[TBL] [Abstract][Full Text] [Related]
8. Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.
Valachis A; Garmo H; Weinman J; Fredriksson I; Ahlgren J; Sund M; Holmberg L
Breast Cancer Res Treat; 2016 Sep; 159(2):293-303. PubMed ID: 27492739
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
10. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.
Ahern TP; Pedersen L; Cronin-Fenton DP; Sørensen HT; Lash TL
Cancer Epidemiol Biomarkers Prev; 2009 Sep; 18(9):2562-4. PubMed ID: 19690182
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
[TBL] [Abstract][Full Text] [Related]
12. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
13. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
14. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
Lash TL; Gurwitz JH; Silliman RA
J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
[TBL] [Abstract][Full Text] [Related]
15. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.
Donneyong MM; Bykov K; Bosco-Levy P; Dong YH; Levin R; Gagne JJ
BMJ; 2016 Sep; 354():i5014. PubMed ID: 27694571
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
17. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence.
Azoulay L; Dell'Aniello S; Huiart L; du Fort GG; Suissa S
Breast Cancer Res Treat; 2011 Apr; 126(3):695-703. PubMed ID: 20848186
[TBL] [Abstract][Full Text] [Related]
18. Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
Busby J; Mills K; Zhang SD; Liberante FG; Cardwell CR
Breast Cancer Res; 2018 Jan; 20(1):4. PubMed ID: 29351761
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen and CYP 2D6 inhibitors: caution.
Prescrire Int; 2011; 20(118):182-4. PubMed ID: 21751753
[TBL] [Abstract][Full Text] [Related]
20. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]